Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) EBITDA (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed EBITDA for 15 consecutive years, with -$4.5 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 17.98% to -$4.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$13.5 million, a 8.17% increase, with the full-year FY2024 number at -$14.7 million, down 10.31% from a year prior.
  • EBITDA was -$4.5 million for Q3 2025 at Plus Therapeutics, down from -$1.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$1.5 million in Q2 2023 to a low of -$5.6 million in Q4 2022.
  • A 5-year average of -$3.7 million and a median of -$3.8 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 150.64% in 2021, then surged 70.9% in 2023.
  • Plus Therapeutics' EBITDA stood at -$3.5 million in 2021, then crashed by 59.25% to -$5.6 million in 2022, then surged by 30.76% to -$3.9 million in 2023, then decreased by 1.09% to -$3.9 million in 2024, then dropped by 14.92% to -$4.5 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's EBITDA are -$4.5 million (Q3 2025), -$1.5 million (Q2 2025), and -$3.5 million (Q1 2025).